摘要
目的：观察匹多莫德联合槐杞黄颗粒及单用匹多莫德治疗儿童反复呼吸道感染的疗效及对机体免疫功能的影响。方法选取159例符合入组标准的反复呼吸道感染患儿，按随机数字表法分为联合治疗组、单项治疗组和对照组，每组各53例，对照组给予退热、祛痰、镇咳、抗感染等常规治疗，联合治疗组在对照组治疗的基础上给予匹多莫德联合槐杞黄颗粒，单项治疗组只给予匹多莫德颗粒，随访6个月，治疗结束后观察患儿症状改善情况，检测 T 细胞亚群比例和免疫球蛋白浓度，进行三组临床疗效评判，随访期间统计复发次数。结果联合治疗组显效率为76%，总有效率为91%；单项治疗组显效率为59%，总有效率为72%；对照组显效率为27%，总有效率为49%，联合治疗组与对照组显效率、总有效率比较差异有统计学意义（P﹤0.01）；单项治疗组与对照组显效率、总有效率比较差异有统计学意义（P﹤0.01）；联合治疗组与单项治疗组显效率、总有效率比较差异有统计学意义（P﹤0.05）。随访期间平均复发次数联合治疗组为（1.5±0.4）次，单项治疗组为（2.3±0.4）次，对照组为（6.0±1.0）次，组间比较差异有统计学意义（P﹤0.01）。组间的退热时间、咳嗽消失时间、扁桃体肿大消退时间、肺部啰音消失时间比较差异均有统计学意义（P﹤0.01）。联合治疗组、单项治疗组治疗后 T 细胞亚群（ CD3﹢、CD4﹢、CD8﹢）、免疫球蛋白（ IgA、IgG、IgM）均较治疗前明显升高，差异有统计学意义；对照组治疗前后 T 细胞亚群、免疫球蛋白差异无统计学意义。结论匹多莫德可有效增强机体抗感染能力，但匹多莫德联合槐杞黄颗粒可显著增强反复呼吸道感染患儿细胞免疫及体液免疫功能，并且能补患儿气阴两虚，能够缓解急性发作期的症状与体征，明显降低疾病的复发次数，值得临床推广使用。
Objective To observe the effect of pidotimod and combined with huaiqihuang（ a traditional Chinese medicine）on recurrent respiratory tract infections and its influence on immune function. Methods One hundred and fifty-nine children with recurrent respiratory tract infections met the inclusion criteria were randomly divided into observation group,pidotimod group and control group,with 53 cases in each group. The control group was given conventional treatment,while the observation group was given pidotimod and huaiqihuang on the basis of conventional treatment,the pidotimod group was given pidotemod on the basis of conventional treatment. After follow-up for 6 months,the symptoms were observed,the levels of T cells subsets and immunoglobulin were detected,the clinical efficacy was evaluated,and the recurrences times were counted. Results The remarkable efficiency of the observation group,pidotimod group and the control group was 76%,59% and 27%,the total efficiency was 91%, 72% and 49%,the recurrences frequency were（1. 5 ± 0. 4）,（2. 3 ± 0. 4）and（ 6. 0 ± 1. 0）times,respectively. There were significant differences between the groups（P﹤0. 01）. The time of defervescence, the disappearing time of coughing and pulmonary signs,and the recovery time of tonsil enlargement among the three groups were significantly different（ P﹤0 . 01 ）. T cell subsets（ CD3﹢,CD4﹢,CD8﹢） and immunoglobulin（ IgA,IgG,IgM）of the observation group and the pidotimod group after treatment were significantly higher than those before treatment. T cell subsets（ CD3﹢,CD4﹢,CD8﹢）,immunoglobulin（ IgA,IgG,IgM）of the observation group and the pidotimod group after treatment was significant-ly higher than that of the control group;there were significant differences. But these indicators of the control group were not changed significantly after treatment. Conclusions Pidotimod can effectively improve the anti-infection ability. The therapy of pidotimod combined with huaiqihuang can significantly enhance the cellular immunity and humoral immunity,assist to alleviate the symptoms and signs of acute exacerbation,and reduce the recurrence frequency,so is worthy of clinical use in the treatment of recurrent respiratory tract infections.
出处
《中国实用医刊》
2014年第16期25-27,共3页
Chinese Journal of Practical Medicine
关键词
反复呼吸道感染
儿童
免疫调节剂
T细胞亚群
免疫球蛋白
Recurrent respiratory tract infections
Children
Immunomodulator
T cell subsets
Immunoglobulin
